Dasatinib has been used:

• as a protein kinase inhibitor to study its effects on macrophage polarization, lipogenesis, western diet-induced progression of simple steatosis into steatohepatitis (NASH), and liver fibrosis in mice
• as an SRC tyrosine kinase inhibitor to study its effects on hepatocellular carcinoma cells
• as a tyrosine kinase inhibitor to study its effects on autophagy in neuronal cells

Dasatinib is a thiazole-carboxamide compound that inhibits a broad spectrum of protein kinases such as breakpoint cluster region-tyrosine protein kinase ABL (Bcr-Abl), Btk family members, platelet-derived growth factor receptor α/β (PDGFR-α/β), and ephrin receptor kinase. It also inhibits Src-family kinases such as SRC tyrosine kinase, and lymphocyte-specific protein kinase (LCK). Dasatinib exhibits certain effects on hematopoietic cells like suppressing natural killer cell toxicity, inhibiting T lymphocytes activation and proliferation, and influencing platelet activation. It is also studied in the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).